- AcelRx Pharmaceuticals (ACRX) announces an EU commercial collaboration agreement with Grunenthal for Zalviso.
- The deal calls for a $30M upfront payment to ACRX — the company will also be eligible for up to $220M in milestone payments tied to regulatory and sales achievements.
- There will also be "tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range" for ACRX.
- ACRX retains rights to Zalviso in countries not covered under the agreement. (PR)
- ACRX +6% premarket
AcelRx rises after inking Zalviso collaboration deal
Dec 16 2013, 09:29 ET